The theory behind Innovative Pricing, and examples of what they could look like, are abundantly available across various mediums (on the off chance you have missed them, you can find an introduction here). With this in mind, I thought a more useful topic to approach might be how to implement these sorts of schemes in the UK.
There is a lot of hype currently around Innovative Pricing. It is one of the ‘buzz words’ of Market Access and loops neatly into the zeitgeist around other topics such as; patient access, effectiveness over efficacy, a more collaborative relationship with payers and physicians etc.
In a recent series of articles, I explored what Real-World Evidence (RWE) is, and why it is needed. In the final part of the series, I gave a worked example of what is possible and hinted that (rather obviously) different styles of study (and different questions) fit at different points in the drug development cycle. This article explores this in more detail, hopefully showing that RWE is not just something to think about after your drug has launched but can support and enhance the process throughout the life cycle.
Innovative Pricing has become a popular subject over the past few years in the pharmaceutical industry. Ever restricting Payer budgets, coupled with increasing competition for treatments and patients has brought into sharp focus the need for a fundamental change in the way we value, price and pay for drugs.
Relvar Ellipta significantly improved asthma control in Salford Lung Study patients compared with their usual care
Pioneering GSK study provides important new data on the effectiveness of Relvar Ellipta (FF/VI) when used in everyday clinical practice
The highly anticipated results from the Salford Lung Study were announced by GSK on 5th May 2017 http://www.gsk.com/en-gb/media/press-releases/relvar-ellipta-significantly-improved-asthma-control-in-salford-lung-study-patients-compared-with-their-usual-care/
Last weekend saw the annual meeting of the Respiratory Effectiveness Group (REG) at the Sheraton Hotel, Heathrow, just outside London take place. For the uninitiated, the REG is one of the world’s leading academic respiratory organisations, dedicated to pushing the envelope of human knowledge in this vital area of patient care. In some ways, of more importance is their particular focus on the clinical impact of their research and findings (how it effects how we should treat and manage respiratory patients in the real world).
Following on from our recent article, Why Real-World Evidence? (which can be found here). This week we take a look at the what data is available for medical research. We hope this will be a useful framework to utilise when trying to decide how best to answer your questions. The next obvious step is to try and work out how to answer them. The simplest way of doing this is to work out what variables you need to test your question, decide on a rough budget, and then consider the options. From my point of view, I find the most effective prism for this assessment comes as the Four Domains of data (see below) which includes all data types and sources possible.
CK Aspire are delighted to have been named a finalist in the EyeforPharma Most Valuable Patient Initiative category in collaboration with GSK on the Salford Lung Study.